We therefore questioned whether the difference in the phospholipid biomarker changes in the PC3 subcutaneous tumours was due to the location of the tumour, and whether growing PC3 tumours orthotopically would result in a different metabolic response to treatment with the AKT inhibitor MK-2206 compared to PC3 subcutaneous tumours. The gene discussed is AKT1; the disease is neoplasm.